Aprea Therapeutics, Inc. Form 8-K Summary
Report date: March 11, 2024; filed March 12, 2024. The filing reports financing, termination of an at-the-market agreement, and regulatory progress. It does not provide a reporting-period income statement, balance sheet, cash flow statement, or operating results.
Business Context and Transaction
Aprea entered into a securities purchase agreement for a private placement expected to close on March 13, 2024, subject to customary closing conditions. The securities are being offered to accredited investors in transactions exempt from Securities Act registration.
- 1,687,712 common shares at $7.29 per share.
- Pre-funded warrants for up to 507,076 common shares at an exercise price of $0.001 per share.
- Tranche A warrants for up to 1,097,394 shares, exercisable at $7.29 per share.
- Tranche B warrants for up to 1,097,394 shares, exercisable at $9.1125 per share.
Financial Metrics and Capitalization
- Expected gross proceeds at closing: approximately $16.0 million.
- Potential future gross proceeds from warrant exercises: approximately $18.0 million.
- The filing does not provide revenue, profit or loss, cash flow, margins, cash balance, debt, liquidity runway, or other period-specific financial metrics.
- The financing may materially increase shares outstanding and could result in additional dilution if the warrants are exercised.
Material Changes and Financing Terms
- The Tranche A warrants expire on the earlier of three years after issuance or specified conditions following announcement of the recommended Phase 2 dose for ATRN-119 and achievement of a $14.58 stock-price threshold for 30 consecutive trading days.
- The Tranche B warrants expire on the earlier of five years after issuance or specified conditions following announcement of the recommended Phase 2 dose for APR-1051 and achievement of an $18.225 stock-price threshold for 30 consecutive trading days.
- Warrants contain beneficial-ownership limitations of 4.99%, or 9.99% if elected by the holder.
- Cashless exercise may be available if resale registration is not effective. The warrants generally lack price-reset, price-protection, and Black-Scholes cash-payment provisions, other than customary adjustment provisions.
- Aprea agreed to file a resale registration statement by the 60th day after closing and use reasonable best efforts to have it effective no later than the 90th day after closing.
- The company and H.C. Wainwright & Co. agreed to terminate the January 26, 2024 at-the-market offering agreement effective March 11, 2024.
Guidance, Outlook, Risks and Unusual Items
- The FDA cleared Aprea’s Investigational New Drug application for APR-1051. The filing does not provide a clinical-development timeline, efficacy data, or financial guidance.
- Future warrant proceeds are contingent on exercise decisions, share-price performance, clinical-development milestones, and applicable registration or cashless-exercise conditions.
- The private placement is subject to closing conditions and was expected to close after the filing date; the filing does not confirm that closing occurred.
- The securities were initially unregistered and may not be resold in the United States absent registration or an applicable exemption.
Key Facts for Investors to Verify
- Whether the private placement closed on or about March 13, 2024 and the actual net proceeds after fees and expenses.
- The resulting common-share count, including shares issued upon exercise of pre-funded or other warrants.
- The effectiveness and timing of the resale registration statement.
- Aprea’s subsequent cash balance, quarterly burn rate, debt, and estimated liquidity runway.
- Development progress for APR-1051 and ATRN-119, including recommended Phase 2 doses and related clinical milestones.
- The full warrant agreements and securities purchase agreement for definitive terms and potential dilution.